Cite
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis:A FIDELITY subgroup analysis
MLA
Perakakis, Nikolaos, et al. “Efficacy of Finerenone in Patients with Type 2 Diabetes, Chronic Kidney Disease and Altered Markers of Liver Steatosis and Fibrosis:A FIDELITY Subgroup Analysis.” Perakakis , N , Bornstein , S R , Birkenfeld , A L , Linkermann , A , Demir , M , Anker , S D , Filippatos , G , Pitt , B , Rossing , P , Ruilope , L M , Kolkhof , P , Lawatscheck , R , Scott , C , Bakris , G L & FIDELIO-DKD and FIGARO-DKD Investigators 2024 , ’ Efficacy of Finerenone in Patients with Type 2 Diabetes, Chronic Kidney Disease and Altered Markers of Liver Steatosis and Fibrosis : A FIDELITY Subgroup Analysis ’ , Diabetes, Obesity and Metabolism , Vol. 26 , No. 1 , Pp. 191-200 , 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1439553916&authtype=sso&custid=ns315887.
APA
Perakakis, N., Bornstein, S. R., Birkenfeld, A. L., Linkermann, A., Demir, M., Anker, S. D., Filippatos, G., Pitt, B., Rossing, P., Ruilope, L. M., Kolkhof, P., Lawatscheck, R., Scott, C., & Bakris, G. L. (2024). Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis:A FIDELITY subgroup analysis. Perakakis , N , Bornstein , S R , Birkenfeld , A L , Linkermann , A , Demir , M , Anker , S D , Filippatos , G , Pitt , B , Rossing , P , Ruilope , L M , Kolkhof , P , Lawatscheck , R , Scott , C , Bakris , G L & FIDELIO-DKD and FIGARO-DKD Investigators 2024 , ’ Efficacy of Finerenone in Patients with Type 2 Diabetes, Chronic Kidney Disease and Altered Markers of Liver Steatosis and Fibrosis : A FIDELITY Subgroup Analysis ’ , Diabetes, Obesity and Metabolism , Vol. 26 , No. 1 , Pp. 191-200 .
Chicago
Perakakis, Nikolaos, Stefan R Bornstein, Andreas L Birkenfeld, Andreas Linkermann, Münevver Demir, Stefan D Anker, Gerasimos Filippatos, et al. 2024. “Efficacy of Finerenone in Patients with Type 2 Diabetes, Chronic Kidney Disease and Altered Markers of Liver Steatosis and Fibrosis:A FIDELITY Subgroup Analysis.” Perakakis , N , Bornstein , S R , Birkenfeld , A L , Linkermann , A , Demir , M , Anker , S D , Filippatos , G , Pitt , B , Rossing , P , Ruilope , L M , Kolkhof , P , Lawatscheck , R , Scott , C , Bakris , G L & FIDELIO-DKD and FIGARO-DKD Investigators 2024 , ’ Efficacy of Finerenone in Patients with Type 2 Diabetes, Chronic Kidney Disease and Altered Markers of Liver Steatosis and Fibrosis : A FIDELITY Subgroup Analysis ’ , Diabetes, Obesity and Metabolism , Vol. 26 , No. 1 , Pp. 191-200 . http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1439553916&authtype=sso&custid=ns315887.